{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:57:51Z","timestamp":1782871071744,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Teva Neuroscience"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study's aims were to determine the efficacy and tolerability of rasagiline, a selective monoamine oxidase inhibitor B, for PD patients with mild cognitive impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients on stable dopaminergic therapy were randomized to adjunct rasagiline 1 mg\/day or placebo in this 24\u2010week, double\u2010blind, placebo\u2010controlled, multisite study. The primary endpoint was mean change from baseline to week 24 on the Scales for Outcomes of Parkinson's Disease\u2010Cognition total score. Key secondary measures included changes in cognition, activities of daily living, motor scores, and Clinical Global Impression of Change, as well as safety and tolerability measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 170 patients randomized, 151 (88.2%) completed the study. Change in Scales for Outcomes of Parkinson's Disease\u2010Cognition scores were not significantly different in the rasagiline and placebo groups (adjusted mean: 1.6 [standard error {SE} = 0.5] vs. 0.8 [SE = 0.5] points; LS means difference = 0.8; 95% confidence interval: \u22120.48, 2.05; <jats:italic>P<\/jats:italic> = 0.22). There were no between\u2010group differences in change in the MoCA (p=0.84) or Penn Daily Activities Questionnaire (<jats:italic>P<\/jats:italic> = 0.48) scores or in the distribution of Alzheimer's Disease Cooperative Study\u2013Clinical Global Impression of Change modified for mild cognitive impairment (<jats:italic>P<\/jats:italic> = 0.1). Changes in motor (UPDRS part III; <jats:italic>P<\/jats:italic> = 0.02) and activities of daily living (UPDRS part II; <jats:italic>P<\/jats:italic> &lt; 0.001) scores favored rasagiline. Rasagiline was well tolerated; the most common adverse events in both groups were falls and dizziness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rasagiline treatment in PD patients with mild cognitive impairment was not associated with cognitive improvement. Rasagiline did not worsen cognition, improved motor symptoms and activities of daily living, and was well tolerated in elderly cognitively impaired patients. \u00a9 2016 International Parkinson and Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.26617","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T18:33:28Z","timestamp":1459449208000},"page":"709-714","source":"Crossref","is-referenced-by-count":61,"title":["Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo\u2010controlled trial"],"prefix":"10.1002","volume":"31","author":[{"given":"Daniel","family":"Weintraub","sequence":"first","affiliation":[{"name":"Departments of Psychiatry and Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Elm","sequence":"additional","affiliation":[{"name":"Department of Public Health Science Medical University of South Carolina Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[{"name":"Georgetown University Medical Center Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals West Chester Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals Overland Park Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the MODERATO Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.3.387"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24893"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f39d0e"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52219.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22643"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.06.011"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23073"},{"key":"e_1_2_8_9_1","first-page":"575","article-title":"Differential contributions of cognitive and motor component processes to physical and instrumental activities of daily living in Parkinson's disease","volume":"13","author":"Cahn D","year":"1998","journal-title":"Arch Clin Neuropsychol"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21853"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.02011.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21686"},{"key":"e_1_2_8_13_1","unstructured":"Changing the trajectory of Alzeheimer's disease: how a treatment by 2025 saves lives and dollars.2015.Alzheimer's Association. Available at:https:\/\/www.alz.org\/documents_custom\/trajectory.pdf. Accessed March 2016."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26352"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26236"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23738"},{"key":"e_1_2_8_17_1","first-page":"165","volume-title":"Clinical Gerontology: A Guide to Assessment and Intervention","author":"Sheikh JI","year":"1986"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22571"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000091864.39702.1C"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26339"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e31819cb760"},{"key":"e_1_2_8_22_1","first-page":"153","volume-title":"Recent Developments in Parkinson's Disease","author":"Fahn S","year":"1987"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.06.006"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.4.2.134"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.130451"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312470130"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.2472"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70212-X"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr031"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-010-0744-4"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23823"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70194-0"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70146-2"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4109"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200007)15:4<664::AID-MDS1010>3.0.CO;2-D"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26617","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:41:02Z","timestamp":1760971262000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/mds.26617"],"URL":"https:\/\/doi.org\/10.1002\/mds.26617","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}